Who makes Cebranopadol 100 µg?

Cebranopadol 100 µg is developed by Tris Pharma, Inc..

What development phase is Cebranopadol 100 µg in?

Cebranopadol 100 µg is in Phase 2.

Last reviewed 2026-04-23 · How we verify

Cebranopadol 100 µg

Tris Pharma, Inc. · Phase 2 active Small molecule

At a glance

Generic name	Cebranopadol 100 µg
Sponsor	Tris Pharma, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Assessment of Abuse Potential of Cebranopadol in Humans (PHASE1)
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cebranopadol 100 µg CI brief — competitive landscape report
Cebranopadol 100 µg updates RSS · CI watch RSS
Tris Pharma, Inc. portfolio CI